Xbira (Abiraterone Acetate) 250 mg

Indicated for the treatment of metastatic castration-resistant prostate cancer (mCRPC) in adult men.

Usage scenarios:

• Chemo-naive patients: Men with asymptomatic or mildly symptomatic disease after failure of androgen deprivation therapy.
• Post-chemo patients: Men whose disease has progressed on or after a docetaxel-containing chemotherapy regimen.

Standard Dosage: 4 tablets (1,000 mg total) taken orally once daily.

⚠️ CRITICAL ADMINISTRATION WARNING:

• 🚫 MUST be taken on an empty stomach.
• No food for at least 2 hours before the dose and 1 hour after the dose.
• Taking Xbira with food causes a dangerous spike in drug absorption (up to 10-fold increase), risking liver toxicity.

Combination: Always take with low-dose prednisone (usually 5 mg twice daily) to prevent mineralocorticoid excess side effects.

• Women who are or may become pregnant (Category X).
• Severe liver impairment (Child-Pugh Class C).
• Hypersensitivity to abiraterone acetate.

Handling precaution: Pregnant women should not handle Xbira tablets without protection (gloves).

Side effects are manageable with prednisone co-administration. Monitor for:

• Fluid retention (peripheral edema).
• Hypokalemia (low potassium levels).
• Hypertension (high blood pressure).
• Elevated liver enzymes (ALT/AST).

Regular blood tests are required to monitor liver function and potassium levels.